Noema Pharma is a company focused on clinical development of first and best-in-class therapeutics targeting orphan neurological disorders. Its management team has a successful track record in the development and commercialization of novel drug therapies for neurological disorders.
The company is developing a pipeline of clinical-stage therapeutic products in-licensed from Roche. Its lead product is targeting patients diagnosed with Tuberous Sclerosis Complex and suffering from persistent seizures and patients diagnosed with Trigeminal Neuralgia (TN), a severe form of neuropathic pain. Other drug candidates in its pipeline are in clinical studies targeting patients diagnosed with Tourette Syndrome and other rare orphan neurological disorders.
Gilde invested in the first financing round of Noema in 2020 when the company in-licensed its product pipeline from Roche.